These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications.
    Author: Le HH, Chang MR, Cheng Q, Lee DA, Hartenbaum D.
    Journal: J Ocul Pharmacol Ther; 1999 Aug; 15(4):305-12. PubMed ID: 10463869.
    Abstract:
    Dorzolamide is the first commercial topical carbonic anhydrase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of glaucoma. In a prospective, open label, uncontrolled study on 245 glaucoma patients, dorzolamide significantly lowered the intraocular pressure at least 14% when used alone or in combination with one, two, or three other antiglaucoma medications over ten weeks. There were very few adverse reactions to dorzolamide. Dorzolamide is effective and safe when used alone or in combination with other topical antiglaucoma medications for the treatment of glaucoma.
    [Abstract] [Full Text] [Related] [New Search]